MétaCan
← all works

Clinical and Immunological Factors in Emphysema Progression: Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD)

2015· article· en· 49 citations· W2186706438 on OpenAlex· 10.1164/rccm.201504-0736oc

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.

The three-model screen

all 1,000 screened works →

All three models called this out of scope.

stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high

Longitudinal clinical cohort study of emphysema progression in COPD.

GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high

This prospective study examines emphysema progression and clinical biomarkers, not research.

Grok 4.5OUT
genre: empirical
about Canada: no
confidence: high

Longitudinal clinical COPD/emphysema study, not metaresearch.

Abstract

RATIONALE: Cross-sectional studies of T-cell responses to self-antigens correlate with baseline emphysema severity. OBJECTIVES: We investigated whether clinical and/or immunological factors could predict disease progression, such as emphysema, FEV1, and 6-minute-walk distance (6MWD), in former and active smokers in a 5-year prospective study. METHODS: We recruited 224 ever smokers over 40 years of age and with greater than a 15 pack-year smoking history. MEASUREMENTS AND MAIN RESULTS: Repeated spirometry, 6MWD, and peripheral blood T-cell cytokine responses to lung elastin fragments were measured. Baseline and repeat chest computed tomography (CT) scans (34 to 65 mo apart) were used to quantify emphysema progression. Of the 141 ever-smokers with baseline and repeat CT scans, the mean (SD) annual rate of change in percent emphysema was +0.46 (0.92), ranging from -1.8 to +4.1. In multivariable analyses, the rate of emphysema progression was greater in subjects who had lower body mass index (BMI) (+0.15 per 5-unit decrease in BMI; 95% confidence interval, +0.03 to +0.29). In active smokers, increased IFN-γ and IL-6 T-cell responses had a positive association with the annual rate of emphysema progression. Male sex and IL-6 T-cell responses to elastin fragments were significantly associated with annual 6MWD decline, whereas IL-13 was associated with an increase in annual 6MWD. CONCLUSIONS: The rate of emphysema progression quantified by CT scans among ever-smokers was highly variable; clinical factors and biomarkers explained only some of the variability. Aggressive clinical care that targets active smokers with autoreactive T cells and low BMI may temporize progression of emphysema.

Stored with the screening record, where it is evidence for the labels above.

The record

Venue
American Journal of Respiratory and Critical Care Medicine
Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Field
Medicine
Canadian institutions
Vancouver General HospitalUniversity of British Columbia
Funders
National Center for Advancing Translational SciencesNational Center for Research ResourcesNational Heart, Lung, and Blood InstituteNational Institutes of HealthU.S. Department of Veterans Affairs
Keywords
MedicineSpirometryInternal medicineBody mass indexCOPDProspective cohort studyExacerbationConfidence intervalCardiologyAsthma
Has abstract in OpenAlex
yes